Condition

MDS (Myelodysplastic Syndrome) clinical trials and research

• 17Clinical trials
• 5Countries

Newest MDS (Myelodysplastic Syndrome) clinical trials

All recruiting trials (17)

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Ivosidenib as maintenance therapy for IDH1-mutated AML or high-risk MDS in patients ineligible for transplant

  This study tests whether continuing ivosidenib after induction helps people with IDH1-mutated AML or high-risk MDS who can’t have a transplant, to see if it helps keep cancer from returning.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07607418

• Haplo-cord Blood Transplant for AML and high-risk MDS

  This study tests a haploidentical-cord blood stem cell transplant approach in patients with AML or high-risk MDS to see how different engraftment patterns affect outcomes.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian and 3 other locations · NCT07588360

• Wearable monitoring to collect health data in people receiving transfusions for blood cancers

  This project will try a wrist-worn accelerometer to see if continuous activity and symptom tracking helps doctors understand and support adults with MDS, AML or related blood cancers who need transfusions.

  Recruiting University of Oxford · Oxford, OXFORDSHIRE · NCT07511829

• Clad-LABU conditioning before allogeneic stem cell transplant for relapsed or refractory AML/MDS in older adults

  This will try a Clad-LABU chemotherapy conditioning plan before allogeneic stem cell transplant in people aged 50 and older with relapsed or refractory AML or MDS.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07500753

• Romiplostim versus daily rhTPO for speeding platelet recovery after donor stem-cell transplant

  This trial will test whether a once-weekly romiplostim injection helps platelets recover faster and safely than daily rhTPO in adults 18–65 with MDS or severe aplastic anemia after a donor stem-cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07400341

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• Romiplostim to speed platelet recovery after haploidentical stem cell transplant

  This trial will test whether weekly romiplostim helps adults with AML, MDS, or other blood cancers recover platelets faster after a haploidentical stem cell transplant.

  Recruiting Phase 1 First Affiliated Hospital of Zhejiang University · Hangzhou · NCT07321626

• Sulforaphane to speed blood‑cell recovery after long‑frozen cord‑blood transplant

  This trial tries sulforaphane to see if it helps adults with high‑risk AML, ALL, or MDS recover blood cells faster after receiving cord blood units frozen for 10 years or more.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjing · NCT07297576

• Luspatercept plus darbepoetin for lower-risk, transfusion-dependent MDS without an SF3B1 mutation

  This trial will try combining luspatercept with darbepoetin to reduce red blood cell transfusions in adults with lower-risk, transfusion-dependent MDS who are SF3B1 wild-type and have endogenous EPO below 500 IU/L.

  Recruiting Phase 2 Yale University · New Haven, Connecticut and 3 other locations · NCT07096297

• Treosulfan vs Melphalan conditioning before allogeneic transplant in AML/MDS

  In this study, adults with AML or MDS who are getting an allogeneic transplant try two different conditioning regimens (Treosulfan or Melphalan) to see which one works better and is easier to tolerate.

  Recruiting at 16 sites Phase 2 Technische Universität Dresden · Aachen and 16 other locations · NCT07025824

• Long-term safety follow-up of ARD103 CAR-T cells in relapsed/refractory AML and MDS

  This long-term follow-up study checks whether ARD103 CAR-T cell therapy remains safe for patients with relapsed or refractory AML or MDS after the initial treatment.

  Recruiting at 3 sites ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06906380

• Monalizumab treatment for patients with blood cancers undergoing stem cell transplantation

  This study is testing if a new treatment called Monalizumab can help people with blood cancers like AML or MDS who are getting stem cell transplants by improving their immune response and reducing the chances of disease returning or complications.

  Recruiting at 2 sites Phase 2 Istituto Clinico Humanitas · Genova, GENOVA and 1 other locations · NCT06892223

• Post-transplant cyclophosphamide strategies to prevent graft-versus-host disease after mismatched unrelated donor stem cell transplant

  This platform tests whether adding different drug combinations with post-transplant cyclophosphamide prevents graft‑versus‑host disease better than the standard regimen for adults getting mismatched unrelated donor peripheral blood stem cell transplants for blood cancers.

  Recruiting at 13 sites Phase 2 Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 12 other locations · NCT06859424

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• Treatment with ARD103 CAR-T therapy for patients with relapsed or refractory AML or MDS

  This study is testing a new CAR-T therapy called ARD103 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome.

  Recruiting at 3 sites Phase 1/2 ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06680752

• Transplanting stem cells to treat severe blood disorders

  This study is testing a new way to use stem cells for treating severe blood disorders to see if it can reduce complications and improve outcomes for patients with conditions like severe aplastic anemia.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Baltimore, Maryland and 1 other locations · NCT01174108

Related topics

Quick answers

How many MDS (Myelodysplastic Syndrome) clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (8 trials), United States (6 trials), United Kingdom (1 trial), Italy (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1/2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →